Björn Redfors et al. JACEP 2017;j.jacep

Slides:

Advertisements

Similar presentations

Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,

Advertisements

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Evidence That D-Dimer Levels Predict Subsequent.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation Chern-En Chiang, Tsu-Juey.

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Management of atrial fibrillation. Patterns of Atrial Fibrillation.

Copyright © 2016 American Medical Association. All rights reserved.

Michala E.F. Pedersen et al. JACEP 2017;3:

Tom F. Brouwer et al. JACEP 2016;2:89-96

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Noriko Kikuchi et al. JACEP 2016;2:

Endothelial Dysfunction in Patients With Lone AF and AF Patients With Comorbidities Compared With That in Controls Comparisons are shown among control.

Waddah Maskoun et al. JACEP 2016;2:

Daniel Frenkel et al. JACEP 2016;2:

Shadi Al Halabi et al. JACEP 2015;1:

Kenshi Hayashi et al. JACEP 2016;2:

Ashish Shukla et al. JACEP 2015;1:41-51

Dileep Raman et al. JACEP 2017;3:

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Pugazhendhi Vijayaraman et al. JACEP 2015;1:

Alexander Sedaghat et al. JACEP 2017;3:71-75

Adam B. Greenbaum et al. JACEP 2015;1:

David F. Katz et al. JACEP 2016;j.jacep

Pablo B. Nery et al. JACEP 2016;2:

Sébastien P.J. Krul et al. JACEP 2015;1:

Dhanunjaya Lakkireddy et al. JACEP 2015;1:

Wesley T. O’Neal et al. JACEP 2016;2:

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Patients with Atrial Fibrillation Switching Emphasis from stroke prevention to stroke and hemorrhage prevention. Michael D. Ezekowitz, MBChB, DPhil, FACC,

Michala E.F. Pedersen et al. JACEP 2016;j.jacep

Stavros Stavrakis et al. JACEP 2015;1:1-13

Imran Niazi et al. JACEP 2017;j.jacep

Peter F. Aziz et al. JACEP 2015;1:62-70

Moussa Mansour et al. JACEP 2017;3:

Mintu P. Turakhia et al. JACEP 2016;2:

Leonard M. Rademakers et al. JACEP 2016;2:

Pouria Alipour et al. JACEP 2017;j.jacep

K.R. Julian Chun et al. JACEP 2017;3:

Prabhat Kumar et al. JACEP 2016;j.jacep

Yoshitaka Kimura et al. JACEP 2016;2:

Emilce Trucco et al. JACEP 2018;j.jacep

Marwan Badri et al. JACEP 2015;1:

Kenshi Hayashi et al. JACEP 2016;2:

Stavros Stavrakis et al. JACEP 2015;1:1-13

David F. Katz et al. JACEP 2017;3:20-28

Moussa Mansour et al. JACEP 2016;j.jacep

Anna Björkenheim et al. JACEP 2017;j.jacep

Alexander Sedaghat et al. JACEP 2016;j.jacep

Ayman A. Hussein et al. JACEP 2017;3:1-9

Mintu P. Turakhia et al. JACEP 2016;2:

Björn Redfors et al. JACEP 2017;j.jacep

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Björn Redfors et al. JACEP 2017;j.jacep

Matthew M. Zipse et al. JACEP 2015;1:94-102

Adam B. Greenbaum et al. JACEP 2015;1:

Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep

Jose C. Pachon M. et al. JACEP 2015;1:

Arman Qamar et al. JACC 2018;71:

(p for noninferiority = 0.01)

Nicole M. Bhave et al. JIMG 2018;11:

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Figure 8. Stroke prevention strategy in patients with AF

Gianluigi Savarese et al. JCHF 2016;4:

Forest plot illustrating the risk ratio of major bleeding

Patient selection process in the present study.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Extraordinary Cases in Stroke Prevention

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

Presentation transcript:

Björn Redfors et al. JACEP 2017;j.jacep.2017.04.024 Flow Chart Flow chart showing patient selection. *Contraindications include hemorrhagic stroke, intracranial bleeding; intraocular bleeding; significant bleeding from the gastrointestinal, genitourinary, or respiratory tract; any bleeding requiring surgical intervention; and aortic dissection or cerebral aneurysm with high risk of bleeding that was not repaired within 3 months. AF = atrial fibrillation; ICD = International Classification of Diseases; LMWH = low-molecular-weight heparin; OAC = oral anticoagulant. Björn Redfors et al. JACEP 2017;j.jacep.2017.04.024 2017 American College of Cardiology Foundation